Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as Add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX

Next Previous
Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as Add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms J-RAPID
  • Sponsors Otsuka Pharmaceutical

    • Most Recent Events

    • 06 Jun 2020 Results pooled analysis of efficacy from 4 trials (RAPID 1, RAPID 2, J-RAPID and RAPID-C), presented at the 21st Annual Congress of the European League Against Rheumatism
    • 04 Jun 2020 According to an UCB media release, post-hoc analysis results from the pooled studies RAPID 1 (NCT00152386), RAPID 2 (NCT00175877), J-RAPID (NCT00791999) and RAPID-C (NCT02151851) were presented at the Annual European Congress of Rheumatology (EULAR) 2020.
    • 23 Apr 2015 According to an Astellas Pharma media release, 4-year data from this study were presented at the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top